Advice
following a full submission:
infliximab (Remicade) is not recommended for use within NHS Scotland for the treatment of ankylosing spondylitis, in patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy.
In one relatively small study, it has demonstrated improvements in signs and symptoms, quality of life and physical functioning. However, there is no evidence of a decrease in joint damage. The economic case is not demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- infliximab (Remicade)
- SMC ID:
- 101/04
- Indication:
- for the treatment of ankylosing spondylitis
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 12 July 2004